Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?- Lorelei Mucci

September 19, 2017

(Length of lecture ~ 19 minutes)

Alicia Morgans hosts a discussion with Lorelei Mucci on her recently-published article in the Journal of Clinical Oncology that reviews a study on the association between statin use and the mortality rate in Danish patients who have prostate cancer. This study leverages the unique data sets available in Scandinavian countries where nationwide health registers can be linked together to perform epidemiologic studies.

Lorelei discusses the challenges of bringing this data forward to a prospective study in the U.S., taking into consideration men with high-risk features, racial diversity of the study population, and whether these men were already using statins before being diagnosed with prostate cancer.  This study concluded that if a man is on a statin at the time of his prostate cancer diagnoses, it appears there is no harm in continuing to take the statins. However, it’s important to have a proof-of-concept trial before determining if postdiagnosis statin use is directly associated with reduced mortality from prostate cancer.

Additional Content on Statin Use in Treating Prostate Cancer:

CUA 2017: Statin Use and Time to Prostate Cancer Progression in Men Undergoing Active Surveillance

AUA 2017: Statin Use, Serum Lipid Levels and Prostate Inflammation; Results from the Reduce Study

AUA 2017: Influence of Statin Intake on PSA Values, Risk of Prostate Cancer Development and Survival in a Prospective Screening Trial Cohort (Erspc Aarau)

Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy

The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer


Alicia Morgans

Lorelei Mucci
Associate Professor of Epidemiology - Harvard T.H. Chan School of Public Health
Boston, MA